Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.05
NYSE:LH's Cash-to-Debt is ranked lower than
97% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. NYSE:LH: 0.05 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:LH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.09 Max: No Debt
Current: 0.05
0.02
No Debt
Equity-to-Asset 0.42
NYSE:LH's Equity-to-Asset is ranked lower than
77% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. NYSE:LH: 0.42 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:LH' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.14  Med: 0.42 Max: 0.91
Current: 0.42
0.14
0.91
Debt-to-Equity 0.97
NYSE:LH's Debt-to-Equity is ranked lower than
80% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.36 vs. NYSE:LH: 0.97 )
Ranked among companies with meaningful Debt-to-Equity only.
NYSE:LH' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05  Med: 0.9 Max: 4.96
Current: 0.97
0.05
4.96
Debt-to-EBITDA 3.58
NYSE:LH's Debt-to-EBITDA is ranked lower than
73% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.77 vs. NYSE:LH: 3.58 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NYSE:LH' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.22  Med: 2.25 Max: 4.36
Current: 3.58
1.22
4.36
Interest Coverage 5.76
NYSE:LH's Interest Coverage is ranked lower than
76% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.01 vs. NYSE:LH: 5.76 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:LH' s Interest Coverage Range Over the Past 10 Years
Min: 4.04  Med: 10.8 Max: 15.09
Current: 5.76
4.04
15.09
Piotroski F-Score: 6
Altman Z-Score: 2.66
Beneish M-Score: -2.33
WACC vs ROIC
9.34%
12.97%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 13.08
NYSE:LH's Operating Margin % is ranked higher than
76% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.59 vs. NYSE:LH: 13.08 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:LH' s Operating Margin % Range Over the Past 10 Years
Min: 12.8  Med: 17.97 Max: 20.22
Current: 13.08
12.8
20.22
Net Margin % 11.52
NYSE:LH's Net Margin % is ranked higher than
84% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.48 vs. NYSE:LH: 11.52 )
Ranked among companies with meaningful Net Margin % only.
NYSE:LH' s Net Margin % Range Over the Past 10 Years
Min: 5.04  Med: 10.08 Max: 12.15
Current: 11.52
5.04
12.15
ROE % 19.85
NYSE:LH's ROE % is ranked higher than
91% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.75 vs. NYSE:LH: 19.85 )
Ranked among companies with meaningful ROE % only.
NYSE:LH' s ROE % Range Over the Past 10 Years
Min: 11.27  Med: 21.47 Max: 28.64
Current: 19.85
11.27
28.64
ROA % 7.86
NYSE:LH's ROA % is ranked higher than
83% of the 262 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.54 vs. NYSE:LH: 7.86 )
Ranked among companies with meaningful ROA % only.
NYSE:LH' s ROA % Range Over the Past 10 Years
Min: 4.09  Med: 8.4 Max: 11.43
Current: 7.86
4.09
11.43
ROC (Joel Greenblatt) % 57.25
NYSE:LH's ROC (Joel Greenblatt) % is ranked higher than
86% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.57 vs. NYSE:LH: 57.25 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:LH' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 57.25  Med: 97.78 Max: 138.05
Current: 57.25
57.25
138.05
3-Year Revenue Growth Rate 13.00
NYSE:LH's 3-Year Revenue Growth Rate is ranked higher than
69% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. NYSE:LH: 13.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:LH' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -21.4  Med: 11.7 Max: 24.4
Current: 13
-21.4
24.4
3-Year EBITDA Growth Rate 10.40
NYSE:LH's 3-Year EBITDA Growth Rate is ranked higher than
51% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. NYSE:LH: 10.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:LH' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -57  Med: 7.8 Max: 157.1
Current: 10.4
-57
157.1
3-Year EPS without NRI Growth Rate 27.40
NYSE:LH's 3-Year EPS without NRI Growth Rate is ranked higher than
74% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. NYSE:LH: 27.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:LH' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 7.1 Max: 82.8
Current: 27.4
0
82.8
GuruFocus has detected 5 Warning Signs with Laboratory Corp of America Holdings NYSE:LH.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:LH's 30-Y Financials

Financials (Next Earnings Date: 2018-07-26)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

LH Guru Trades in Q3 2017

Ken Fisher 65,497 sh (New)
Ray Dalio 42,662 sh (New)
George Soros 54,000 sh (New)
Jim Simons 625,805 sh (+23.58%)
Larry Robbins 2,908,188 sh (+9.13%)
John Hussman 500 sh (unchged)
Mario Gabelli 3,400 sh (unchged)
Jeff Auxier 1,775 sh (unchged)
David Dreman 4,961 sh (unchged)
Steven Cohen Sold Out
Wallace Weitz 761,375 sh (-0.36%)
Scott Black 15,300 sh (-8.30%)
John Rogers 1,247,988 sh (-9.88%)
Joel Greenblatt 102,510 sh (-19.68%)
Charles Brandes 67,876 sh (-36.35%)
First Pacific Advisors 16,560 sh (-47.64%)
Richard Snow 14,110 sh (-61.68%)
» More
Q4 2017

LH Guru Trades in Q4 2017

Pioneer Investments 132,182 sh (New)
Leucadia National 3,129 sh (New)
John Hussman 15,500 sh (+3000.00%)
David Dreman 12,263 sh (+147.19%)
George Soros 109,000 sh (+101.85%)
Mario Gabelli 6,400 sh (+88.24%)
Jim Simons 750,099 sh (+19.86%)
First Pacific Advisors 19,560 sh (+18.12%)
Joel Greenblatt 103,794 sh (+1.25%)
Scott Black 15,359 sh (+0.39%)
Richard Snow 14,110 sh (unchged)
Ray Dalio Sold Out
Wallace Weitz 758,675 sh (-0.35%)
Jeff Auxier 1,750 sh (-1.41%)
John Rogers 1,222,610 sh (-2.03%)
Ken Fisher 61,395 sh (-6.26%)
Charles Brandes 62,400 sh (-8.07%)
Larry Robbins 2,670,426 sh (-8.18%)
» More
Q1 2018

LH Guru Trades in Q1 2018

Pioneer Investments 835,557 sh (+532.13%)
Leucadia National 10,594 sh (+238.57%)
Joel Greenblatt 260,681 sh (+151.15%)
George Soros 242,781 sh (+122.73%)
Richard Snow 25,610 sh (+81.50%)
Jim Simons 911,405 sh (+21.50%)
John Hussman 15,500 sh (unchged)
Mario Gabelli 6,400 sh (unchged)
Ken Fisher 60,615 sh (-1.27%)
Wallace Weitz 747,684 sh (-1.45%)
John Rogers 1,186,682 sh (-2.94%)
David Dreman 11,660 sh (-4.92%)
Scott Black 14,222 sh (-7.40%)
Charles Brandes 57,585 sh (-7.72%)
Jeff Auxier 1,575 sh (-10.00%)
First Pacific Advisors 16,930 sh (-13.45%)
Larry Robbins 1,856,832 sh (-30.47%)
» More
Q2 2018

LH Guru Trades in Q2 2018

Ken Fisher 58,909 sh (-2.81%)
» More
» Details

Insider Trades

Latest Guru Trades with LH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2018-06-30 Reduce -2.81%$160.33 - $189.41 $ 187.667%58,909
John Rogers 2018-03-31 Reduce -2.94%0.06%$161.53 - $178.11 $ 187.6610%1,186,682
Wallace Weitz 2018-03-31 Reduce -1.45%0.08%$161.53 - $178.11 $ 187.6610%747,684
Joel Greenblatt 2018-03-31 Add 151.15%0.36%$161.53 - $178.11 $ 187.6610%260,681
George Soros 2018-03-31 Add 122.73%0.4%$161.53 - $178.11 $ 187.6610%242,781
Ken Fisher 2018-03-31 Reduce -1.27%$161.53 - $178.11 $ 187.6610%60,615
Charles Brandes 2018-03-31 Reduce -7.72%0.02%$161.53 - $178.11 $ 187.6610%57,585
David Dreman 2018-03-31 Reduce -4.92%0.05%$161.53 - $178.11 $ 187.6610%11,660
Leucadia National 2018-03-31 Add 238.57%0.08%$161.53 - $178.11 $ 187.6610%10,594
John Rogers 2017-12-31 Reduce -2.03%0.04%$147.99 - $163.95 $ 187.6622%1,222,610
Wallace Weitz 2017-12-31 Reduce -0.35%0.02%$147.99 - $163.95 $ 187.6622%758,675
George Soros 2017-12-31 Add 101.85%0.24%$147.99 - $163.95 $ 187.6622%109,000
Joel Greenblatt 2017-12-31 Add 1.25%$147.99 - $163.95 $ 187.6622%103,794
Charles Brandes 2017-12-31 Reduce -8.07%0.02%$147.99 - $163.95 $ 187.6622%62,400
Ken Fisher 2017-12-31 Reduce -6.26%$147.99 - $163.95 $ 187.6622%61,395
David Dreman 2017-12-31 Add 147.19%0.65%$147.99 - $163.95 $ 187.6622%12,263
Mario Gabelli 2017-12-31 Add 88.24%$147.99 - $163.95 $ 187.6622%6,400
Leucadia National 2017-12-31 New Buy0.04%$147.99 - $163.95 $ 187.6622%3,129
John Rogers 2017-09-30 Reduce -9.88%0.25%$149.47 - $161.17 $ 187.6621%1,247,988
Wallace Weitz 2017-09-30 Reduce -0.36%0.02%$149.47 - $161.17 $ 187.6621%761,375
Joel Greenblatt 2017-09-30 Reduce -19.68%0.06%$149.47 - $161.17 $ 187.6621%102,510
Charles Brandes 2017-09-30 Reduce -36.35%0.09%$149.47 - $161.17 $ 187.6621%67,876
Ken Fisher 2017-09-30 New Buy0.01%$149.47 - $161.17 $ 187.6621%65,497
George Soros 2017-09-30 New Buy0.24%$149.47 - $161.17 $ 187.6621%54,000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8071
Compare:NAS:IDXX, XSWX:LONN, TSE:6869, NYSE:IQV, NYSE:A, NYSE:DGX, XTER:SRT3, SZSE:300676, XPAR:BIM, XPAR:ERF, NYSE:PKI, NYSE:BIO, NYSE:QGEN, NAS:DXCM, NAS:ICLR, NAS:EXAS, XTER:AFX, NAS:PRAH, MIL:DIA, NYSE:CRL » details
Traded in other countries:LAB.Germany, LH.Mexico,
Headquarter Location:USA
Laboratory Corp of America Holdings is a healthcare diagnostics company. It is engaged in providing comprehensive clinical laboratory and end-to-end drug development services. It operates in two segments: LabCorp Diagnostics and Covance Drug Development.

Laboratory Corporation of America is the nation's second- largest independent clinical laboratory, with roughly 20% of the independent lab market. The company operates more than 1,800 patient-service centers, offering a broad range of clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing. With the addition of Covance, LabCorp also has a sizable footprint in the global contract research organization market.

Guru Investment Theses on Laboratory Corp of America Holdings

Weitz Funds Comments on Laboratory Corp. of America - May 18, 2017

Laboratory Corp. of America (LabCorp) (NYSE:LH) operates as a diversified global life sciences company through two segments: LabCorp Diagnostics and Covance Drug Development. Following a choppy 2016 third quarter, LabCorp’s fourth quarter operating results resumed a more normal course. Test volumes rebounded at LabCorp Diagnostics, as did new clinical trial bookings at Covance. The company closed the year on a high note, with sales increasing 11% and cash earnings per share up 12% versus the prior year. Underlying clinical lab trends remain stable and the pace of clinical research outsourcing continues to be healthy. Anticipated cuts in Medicare reimbursement for lab tests and a gradual shift by payers toward value-based payment models are creating new, long hoped-for opportunities for LabCorp’s low cost lab network. LabCorp announced the acquisition of two valuable hospital- based labs during the first quarter and continues to see a steady flow of attractive potential ‘tuck-in’ lab acquisition opportunities. The company’s combination of durable organic growth and significant reinvestment runway remains appealing to us as long-term investors



From Weitz Funds' first-quarter 2017 Balanced Fund shareholder letter.



Check out Wallace Weitz latest stock trades

Wally Weitz Comments on Laboratory Corp of America - Jul 20, 2016

Laboratory Corp. of America (NYSE:LH) is a healthcare diagnostics company providing comprehensive clinical laboratory services to medical professionals and end-to-end drug development support to pharmaceutical manufacturers. LabCorp reported stronger than expected organic growth during the first quarter in both its diagnostics and drug development segments and raised its financial forecast for the full year. Covance, its drug development segment, has demonstrated improving operating momentum the past three quarters, with strength across each of its primary end markets (pre-clinical, central lab, late stage). Finally, the Center for Medicare and Medicaid Services’ (CMS’) highly anticipated Final Rule on changes to the Medicare Clinical Lab Fee Schedule in mid-June included two positives for the lab industry – a delay in implementation until 2018 and the inclusion of higher cost outpatient hospital labs, which is a piece that will determine future reimbursement levels. While final details won’t be known for some time, we anticipate these reimbursement changes will have a very modest impact on LabCorp’s future earnings power.



From Weitz Partners Fund's second quarter 2016 commentary.



Check out Wallace Weitz latest stock trades

Top Ranked Articles about Laboratory Corp of America Holdings

Ariel Funds' Charlie Bobrinskoy Taking GuruFocus User Questions Ask an investing question to a pro!
We’re excited to bring Charlie Bobrinksoy as the next investment professional for a Q&A. Read more...
Ariel Investments on the Future of Health Care Recommends 10 health care names
Ariel Investments, run by John Rogers (Trades, Portfolio), just published an interesting monthly commentary I'll shortly discuss. Very quickly -- who is John Rogers (Trades, Portfolio)? GuruFocus profiles Rogers as follows: Read more...
George Soros' High-Conviction Picks The guru loaded up on shares of these three high-performers by as much as 500% over two consecutive quarters
George Soros (Trades, Portfolio)’ high-conviction stock picks in two consecutive quarters are among some of the best performers of the S&P 500. Read more...
LabCorp and Philips collaborate on digital pathology to enhance the efficiency of pathology diagnostics
OmniSeq and LabCorp Launch OmniSeq Advance℠ Assay
New Research Coverage Highlights Internap, Dime Community Bancshares, Cohu, Laboratory Corporation of America, Energy Fuels, and Obsidian Energy — Consolidated Revenues, Company Growth, and Expectations for 2018
Hitachi High-Tech Participates in OmniSeq Series B and Secures Japanese Distribution Rights
US Ecology, Inc. Announces Appointment of Glenn A. Eisenberg to Its Board of Directors
Analysts Take Action on Healthcare Stocks Companies under review included LabCorp, Quest Diagnostics, Allergan, AbbVie and Humira
Analysts took action on healthcare stocks. Read more...
Wall Street Retreats on Monday Seagate earnings beat
Despite the biggest increase in household buying since 2011, U.S. stock markets are set to open in the red on Monday. Consumer spending climbed 0.4% the past month, due to bigger incomes, which rose 0.4% in December and registered a total of 3.1% for the full year. Read more...

Ratios

vs
industry
vs
history
PE Ratio 15.59
LH's PE Ratio is ranked higher than
88% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.00 vs. LH: 15.59 )
Ranked among companies with meaningful PE Ratio only.
LH' s PE Ratio Range Over the Past 10 Years
Min: 12.89  Med: 16.81 Max: 29.28
Current: 15.59
12.89
29.28
Forward PE Ratio 16.18
LH's Forward PE Ratio is ranked higher than
95% of the 40 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. LH: 16.18 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 15.59
LH's PE Ratio without NRI is ranked higher than
88% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.56 vs. LH: 15.59 )
Ranked among companies with meaningful PE Ratio without NRI only.
LH' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.89  Med: 16.81 Max: 29.28
Current: 15.59
12.89
29.28
Price-to-Owner-Earnings 19.28
LH's Price-to-Owner-Earnings is ranked higher than
82% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.75 vs. LH: 19.28 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
LH' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.35  Med: 14.26 Max: 42.34
Current: 19.28
9.35
42.34
PB Ratio 2.74
LH's PB Ratio is ranked higher than
71% of the 245 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.02 vs. LH: 2.74 )
Ranked among companies with meaningful PB Ratio only.
LH' s PB Ratio Range Over the Past 10 Years
Min: 2.11  Med: 3.29 Max: 5.13
Current: 2.74
2.11
5.13
PS Ratio 1.80
LH's PS Ratio is ranked higher than
76% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.81 vs. LH: 1.80 )
Ranked among companies with meaningful PS Ratio only.
LH' s PS Ratio Range Over the Past 10 Years
Min: 1.2  Med: 1.6 Max: 2.49
Current: 1.8
1.2
2.49
Price-to-Free-Cash-Flow 18.15
LH's Price-to-Free-Cash-Flow is ranked higher than
84% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.22 vs. LH: 18.15 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
LH' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.14  Med: 14.49 Max: 32.39
Current: 18.15
9.14
32.39
Price-to-Operating-Cash-Flow 14.03
LH's Price-to-Operating-Cash-Flow is ranked higher than
80% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.94 vs. LH: 14.03 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
LH' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.46  Med: 11.24 Max: 21.23
Current: 14.03
7.46
21.23
EV-to-EBIT 19.09
LH's EV-to-EBIT is ranked higher than
71% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.06 vs. LH: 19.09 )
Ranked among companies with meaningful EV-to-EBIT only.
LH' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.6  Med: 11.8 Max: 21.6
Current: 19.09
8.6
21.6
EV-to-EBITDA 13.55
LH's EV-to-EBITDA is ranked higher than
73% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.75 vs. LH: 13.55 )
Ranked among companies with meaningful EV-to-EBITDA only.
LH' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.1  Med: 9.6 Max: 16.2
Current: 13.55
7.1
16.2
EV-to-Revenue 2.37
LH's EV-to-Revenue is ranked higher than
73% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. LH: 2.37 )
Ranked among companies with meaningful EV-to-Revenue only.
LH' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.6  Med: 2 Max: 2.9
Current: 2.37
1.6
2.9
PEG Ratio 2.07
LH's PEG Ratio is ranked higher than
65% of the 48 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.26 vs. LH: 2.07 )
Ranked among companies with meaningful PEG Ratio only.
LH' s PEG Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.64 Max: 6.3
Current: 2.07
0.74
6.3
Shiller PE Ratio 28.40
LH's Shiller PE Ratio is ranked higher than
79% of the 39 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.49 vs. LH: 28.40 )
Ranked among companies with meaningful Shiller PE Ratio only.
LH' s Shiller PE Ratio Range Over the Past 10 Years
Min: 18.72  Med: 23.87 Max: 48.54
Current: 28.4
18.72
48.54
Current Ratio 1.38
LH's Current Ratio is ranked lower than
80% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.58 vs. LH: 1.38 )
Ranked among companies with meaningful Current Ratio only.
LH' s Current Ratio Range Over the Past 10 Years
Min: 0.47  Med: 1.62 Max: 4.38
Current: 1.38
0.47
4.38
Quick Ratio 1.27
LH's Quick Ratio is ranked lower than
74% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. LH: 1.27 )
Ranked among companies with meaningful Quick Ratio only.
LH' s Quick Ratio Range Over the Past 10 Years
Min: 0.44  Med: 1.52 Max: 4.38
Current: 1.27
0.44
4.38
Days Inventory 10.66
LH's Days Inventory is ranked higher than
90% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.76 vs. LH: 10.66 )
Ranked among companies with meaningful Days Inventory only.
LH' s Days Inventory Range Over the Past 10 Years
Min: 10.44  Med: 12.05 Max: 13.23
Current: 10.66
10.44
13.23
Days Sales Outstanding 54.30
LH's Days Sales Outstanding is ranked higher than
67% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.51 vs. LH: 54.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
LH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.64  Med: 49.42 Max: 54.3
Current: 54.3
44.64
54.3
Days Payable 25.59
LH's Days Payable is ranked lower than
78% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. LH: 25.59 )
Ranked among companies with meaningful Days Payable only.
LH' s Days Payable Range Over the Past 10 Years
Min: 22.15  Med: 28.76 Max: 34.68
Current: 25.59
22.15
34.68

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -6.40
LH's 3-Year Average Share Buyback Ratio is ranked higher than
58% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.90 vs. LH: -6.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -42.1  Med: 1.2 Max: 6.6
Current: -6.4
-42.1
6.6

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.21
LH's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
87% of the 75 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. LH: 1.21 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
LH' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.56  Med: 1.07 Max: 4.87
Current: 1.21
0.56
4.87
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.26
LH's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
88% of the 17 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.86 vs. LH: 1.26 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
LH' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.75  Med: 1.07 Max: 2.47
Current: 1.26
0.75
2.47
Price-to-Median-PS-Value 1.12
LH's Price-to-Median-PS-Value is ranked lower than
54% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. LH: 1.12 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
LH' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.07  Med: 1.03 Max: 3
Current: 1.12
0.07
3
Price-to-Peter-Lynch-Fair-Value 1.88
LH's Price-to-Peter-Lynch-Fair-Value is ranked higher than
53% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.01 vs. LH: 1.88 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
LH' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.53  Med: 1.62 Max: 7.78
Current: 1.88
0.53
7.78
Earnings Yield (Greenblatt) % 5.25
LH's Earnings Yield (Greenblatt) % is ranked higher than
87% of the 265 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.98 vs. LH: 5.25 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
LH' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.6  Med: 8.5 Max: 11.7
Current: 5.25
4.6
11.7
Forward Rate of Return (Yacktman) % 12.41
LH's Forward Rate of Return (Yacktman) % is ranked higher than
60% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.45 vs. LH: 12.41 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
LH' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 10  Med: 16.4 Max: 25.2
Current: 12.41
10
25.2

More Statistics

Revenue (TTM) (Mil) $10,842.70
EPS (TTM) $ 12.04
Beta1.41
Volatility15.13%
52-Week Range $146.68 - 190.36
Shares Outstanding (Mil)102.30

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 11,434 11,869 12,272
EBIT (Mil $) 1,655 1,754 1,976
EBITDA (Mil $) 2,132 2,241 2,351
EPS ($) 9.93 10.97 12.84
EPS without NRI ($) 9.93 10.97 12.84
EPS Growth Rate
(Future 3Y To 5Y Estimate)
8.28%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}